logo
Vaccinations to prevent cervical cancer have plummeted in Britain

Vaccinations to prevent cervical cancer have plummeted in Britain

Hindustan Times4 days ago
HUMAN PAPILLOMAVIRUS (HPV) is an unwelcome consequence of a joyful pursuit. Skin-to-skin contact during sex allows the virus to spread, which can lead to genital warts and cancers of the reproductive system. In Britain HPV causes about 3,500 cases of cervical cancer each year and 900 deaths. A vaccination programme that inoculates against the virus—once a runaway success—is floundering.
The HPV vaccine is given to children aged between 12 and 15 before they are typically sexually active. Take-up in girls was around 90% in the years up to 2017. Today the rate foryear-ninegirls is 74%, on a par with Sierra Leone. In boys, who have been offered the jab for five years, it has fallen by nine percentage points to 69%. In some areas, such as Luton and Leicester, less than half of children are vaccinated.
Chart
Vaccination rates have fallen in all of Britain's child-immunisation programmes, but the drop is sharpest for HPV. The evidence of the vaccine's efficacy is unequivocal: a study from Scotland in 2024 found no cases of cancer-causing HPV virus among women who received it a decade earlier. The National Health Service (NHS) wants to eliminate cervical cancer by 2040, but says it needs to achieve a 90% vaccination rate by 2030. To do so means tackling the three Cs of vaccine hesitancy: confidence, convenience and complacency.
Confidence in vaccines was dented during the coronavirus pandemic. Surveys conducted by the Vaccine Confidence Project (VCP), a research outfit, find that the share of respondents who agreed that vaccines are 'safe' and 'important for children' declined sharply during the pandemic in many countries, but the drop was especially pronounced in Britain.
New survey data from the VCP on vaccine attitudes in Britain, shared exclusively with The Economist, show that confidence in vaccines in general has since improved. Among a representative sample of adults, 85% agree that 'in general, vaccines are safe', 15 percentage points up on 2023. But when asked specifically about the safety of the HPV vaccine, that figure drops to 74%.
Blame disinformation. Anti-vax parents allege that it causes ovarian failure and other issues. In 2019 Robert F. Kennedy junior, now America's health secretary, called it 'the most dangerous vaccine ever invented'. Numerous studies have found that its adverse effects are similar to, and no more frequent than, other common vaccines. The UK Health Security Agency (UKHSA) says that the rates of ovarian failure and other illnesses are no greater than would occur naturally in adolescent girls.
Are today's schoolchildren affected by anti-vax views? Surveys of teenagers show that they know where to seek information they trust about vaccines: from their parents. Worryingly, the latest VCP survey shows that middle-aged people (ie, the parents of teenagers) are the least likely to say the HPV vaccine is safe.
The HPV vaccine is administered in schools, but parents must sign a form to consent to their child being inoculated. The UKHSA says that many go unsigned, not because a parent actively objects but because of a lack of convenience. It wants to tackle this by allowing children to self-consent if the nurse giving the vaccine believes that they are mature enough—though only one in five teenagers say they alone should decide whether to get vaccinated, rising to one in three by age 16.
Some parents worry that vaccination might affect their child's behaviour. Dr Tehseen Khan, a GP in the London borough of Hackney, says Orthodox Jews he works with believe the vaccine is unnecessary because their children will have only one life-long partner. Although there is no evidence that having the vaccine changes sexual behaviour, some parents fear that it promotes promiscuity. In Scotland, which (unlike England) publishes data by ethnicity, Pakistani and Polish children have the lowest HPV vaccination rates; white British and Chinese the highest.
Complacency may also lead children and parents to wonder why the vaccine is necessary. Helen Bedford of University College London says parents often ask: 'Why do I need to get my child who is not yet sexually active vaccinated against something which may or may not happen to them in 20 or 30 years time?' Vaccination programmes are often victims of their own success, making cervical cancer less common and parents less worried about it.
The NHS recently launched a catch-up campaign, targeting some 400,000 women aged under 25 who did not get inoculated in school. Whether they will get a jab may not be down to the facts. Margaret Stanley at the University of Cambridge, whose research helped develop the HPV vaccine, says at this stage you should 'forget the science, it's all about the marketing.'
For more expert analysis of the biggest stories inBritain,sign upto Blighty, our weekly subscriber-only newsletter.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HPV vaccination drive held for girl students of municipal schools
HPV vaccination drive held for girl students of municipal schools

The Hindu

time11 hours ago

  • The Hindu

HPV vaccination drive held for girl students of municipal schools

Digumarti Foundation, in association with Manavseva of Boston, organised a cervical cancer prevention programme for adolescent girls from municipal schools in Akkireddypalem and Gajuwaka at KIMS ICON Hospital on Sunday. Over 200 girls received the Human Papillomavirus (HPV) vaccine, which protects against most cervical cancer cases. Mothers were also screened for cervical pre-cancer using the HPV DNA test by Dr. Leela Digumarti, enabling early detection and treatment. BJP State president P.V.N. Madhav, the chief guest, urged the public to adopt preventive measures such as natural diets and traditional practices to reduce cancer risk. Dr. Raghunath Rao, founder-director of Homi Bhabha Cancer Hospital, said children aged 9–14 will be given two doses over six months, while those aged 15–21 will receive three doses. Once imported, the HPV vaccine is now manufactured in India and has been administered to over 5,000 people. It is effective against six types of cancer.

Precigen shares jump after U.S. FDA approves first therapy for rare respiratory disease
Precigen shares jump after U.S. FDA approves first therapy for rare respiratory disease

The Hindu

time15 hours ago

  • The Hindu

Precigen shares jump after U.S. FDA approves first therapy for rare respiratory disease

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for the condition, which typically requires frequent surgeries, sending the company's shares soaring 83% on Friday. The U.S. Food and Drug Administration has approved the therapy, Papzimeos, to treat adults with recurrent respiratory papillomatosis (RRP) — a condition that causes growth of benign tumors in the respiratory tract due to human papillomavirus (HPV) infection. A distinguishing aspect of RRP is the tendency for the tumors to return even after removing them through surgical procedures. The disease can be fatal as there is no cure. The FDA approval was based on an early-to-mid-stage study data that showed 51% of patients required no surgeries in the 12 months after the treatment. "Randomised trials are not always needed to approve medical products and this approval is proof of that philosophy," said Vinay Prasad, who recently returned to the FDA to oversee vaccine, gene therapy and blood product regulation. Papzimeos is designed to stimulate an immune response against cells infected with HPV types 6 and 11 — the strains that cause the disease. H.C. Wainwright analysts estimate peak sales of the drug to reach $1.1 billion in 2033. "We may finally be able to say no more surgery," said Kim McClellan, president of the Recurrent Respiratory Papillomatosis Foundation. McClellan herself was diagnosed with RRP at the age of five and has since then had more than 250 surgeries. Precigen estimates about 27,000 adult RRP patients in the U.S. It did not immediately respond to a Reuters request for comment on the treatment's pricing. Simon Best, associate professor of Otolaryngology at Johns Hopkins Hospital, said patients were eagerly awaiting a new treatment. "There's nothing more frustrating than doing a surgery and then having the patient come back six months later."

Why protecting your child from certain preventable cancers should be a top priority
Why protecting your child from certain preventable cancers should be a top priority

Time of India

timea day ago

  • Time of India

Why protecting your child from certain preventable cancers should be a top priority

*IMAGE FOR REPRESENTATION PURPOSE ONLY As a parent, you plan various aspects of your child's future. But it is easy to overlook a key investment during their teen years: their health. This is an important time in their life when the foundations for future well-being can be laid which can make a huge difference. You were diligent with the childhood immunisation shots, and that protection continues. But did you know that there is prevention available including vaccination for certain types of cancers like cervical cancer, anal cancer? These are caused by HPV or the human papilloma virus – a commonly transmitted virus that often functions silently and may not show any symptoms. While most HPV infections clear on their own, but if it persists, it can lead to certain types of cancers and other complications. Like any good investment, in health as well, acting early can yield better results. Taking preventive steps for your child during adolescence with HPV vaccination , between 9 and 14 years old, can yield better protection against certain HPV related cancers and diseases compared to when vaccinated later. At this age, their bodies build a more lasting immunity, providing strong protection before they are at risk of certain HPV related cancers and diseases. And this is not just for girls. HPV poses a risk of various cancers in both men and women. Protecting both boys and girls helps reduce some of these HPV related risks. We often see investment in health as 'optional' step because it's not an immediate risk, but a small investment today is nothing compared to the cost of a future illness. Prevention and protection are one of the important tools we have today against certain HPV related cancers. If you have questions, you are not alone. The best first step is a simple chat with your child's paediatrician, who can answer your questions and guide you. Don't wait, the earlier this protection begins, the better it may be. It is a simple step that can help protect your child against risk of certain HPV related cancers and diseases. Issued in public interest by MSD Pharmaceuticals for awareness purposes. References: 1. Questions and Answers about Human Papillomavirus (HPV). WHO (regional office for Europe) 2020, accessed on 2nd July 2025 2. HPV FAQ & Questions | Help You Understand Diagnosis & Treatment. Accessed on 2nd July 2025 IN-GSL-01402 25-Jul 2025 24-Jul 2027 Disclaimer : The views and opinions expressed in the story are independent professional judgments of the experts, and TIL does not take any responsibility for the accuracy of their views. This article has been produced on behalf of MSD Pharmaceuticals by Times Internet's Spotlight team.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store